KA Imaging Appoints World-Renowned Radiologist, Dr. Philip Templeton, as Chief Medical Officer

March 8, 2021

KA Imaging notes Dr. Philip Templeton brings over 38 years of academic and entrepreneurial medicine experience to KA Imaging.

Dr. Philip Templeton is most recently known as Cofounder and Chief Medical Officer of DocPanel Technologies. A graduate and valedictorian at the University of Rochester School of Medicine, he did his internship in Medicine at the Georgetown University Hospital. His radiology residency was at the University of Maryland, where he also served as Chief Resident. He undertook his Thoracic Radiology Fellowship at the Massachusetts General Hospital. He served as Professor and Chairman of University of Maryland Radiology for ten years.  Dr. Templeton was inducted as a Fellow of the American College of Radiology in 2000.

Among his many career accomplishments, Dr. Templeton was a pioneer in the use of several groundbreaking technologies, including CT fluoroscopy, digital X-ray, PACS and teleradiology.

“In addition to being a skilled physician, Philip is a seasoned corporate leader with a strong track record of delivering medical, scientific and strategic guidance to both established and emerging companies in the medical imaging space,” said Amol Karnick, CEO of KA Imaging. “We are delighted to welcome him as CMO. Philip will provide a strong liaison with our customers, and ensure that our clinical programs are designed to meet the needs of both clinicians and patients.”

Dr. Templeton’s appointment comes on the heels of the recent additions of two other seasoned industry veterans – Shawn Campbell as Vice President of Operations and Robert Moccia as Vice President of Sales, USA and Canada – as KA Imaging executes its commercial roll-out of Reveal™ 35C, the world’s first portable, single exposure, dual-energy X-ray detector that enables bone and soft tissue differentiation without motion artifacts.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”